X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14) 14
oncology (14) 14
female (13) 13
index medicus (13) 13
aged (11) 11
lung neoplasms - drug therapy (11) 11
carcinoma, non-small-cell lung - drug therapy (10) 10
male (10) 10
middle aged (10) 10
adult (9) 9
hematology, oncology and palliative medicine (9) 9
lung cancer, non-small cell (8) 8
lung neoplasms - genetics (7) 7
antineoplastic agents - therapeutic use (6) 6
carcinoma, non-small-cell lung - genetics (6) 6
carcinoma, non-small-cell lung - pathology (6) 6
chemotherapy (6) 6
lung cancer (6) 6
lung neoplasms - mortality (6) 6
lung neoplasms - pathology (6) 6
pyrazoles - therapeutic use (6) 6
pyridines - therapeutic use (6) 6
treatment outcome (6) 6
aged, 80 and over (5) 5
cancer (5) 5
carcinoma, non-small-cell lung - mortality (5) 5
care and treatment (5) 5
gefitinib (5) 5
inhibitor (5) 5
protein kinase inhibitors - therapeutic use (5) 5
adenocarcinoma (4) 4
article (4) 4
disease-free survival (4) 4
kaplan-meier estimate (4) 4
mutation (4) 4
receptor protein-tyrosine kinases - antagonists & inhibitors (4) 4
resistance (4) 4
adenocarcinoma - genetics (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
carcinoma, non-small-cell lung - enzymology (3) 3
erlotinib (3) 3
follow-up studies (3) 3
gene amplification (3) 3
genetic aspects (3) 3
lung neoplasms - enzymology (3) 3
medical colleges (3) 3
metastasis (3) 3
neoplasm staging (3) 3
open-label (3) 3
research (3) 3
therapy (3) 3
adenocarcinoma - drug therapy (2) 2
analysis (2) 2
anaplastic lymphoma kinase (2) 2
antineoplastic agents - adverse effects (2) 2
biomarkers, tumor - analysis (2) 2
c-met (2) 2
cancer therapies (2) 2
carbazoles - adverse effects (2) 2
carbazoles - therapeutic use (2) 2
ch5424802 (2) 2
crizotinib (2) 2
ctdna (2) 2
dose-response relationship, drug (2) 2
drug administration schedule (2) 2
drug resistance, neoplasm (2) 2
drug therapy (2) 2
egfr (2) 2
egfr mutations (2) 2
eml4-alk fusion gene (2) 2
epidermal growth factor (2) 2
gene rearrangement (2) 2
molecular targeted therapy (2) 2
mutation - genetics (2) 2
non-small cell lung cancer (2) 2
oncology, experimental (2) 2
ovarian cancer (2) 2
patient outcomes (2) 2
patient selection (2) 2
patients (2) 2
pharmaceutical industry (2) 2
piperidines - adverse effects (2) 2
piperidines - therapeutic use (2) 2
prognosis (2) 2
progression (2) 2
proportional hazards models (2) 2
protein kinase inhibitors - adverse effects (2) 2
proto-oncogene proteins c-met - genetics (2) 2
pulmonary/respiratory (2) 2
quinazolines - therapeutic use (2) 2
rearrangements (2) 2
receptor protein-tyrosine kinases - analysis (2) 2
receptor protein-tyrosine kinases - genetics (2) 2
receptor, epidermal growth factor - genetics (2) 2
respiratory system (2) 2
risk assessment (2) 2
safety and security measures (2) 2
survival (2) 2
survival analysis (2) 2
survival rate (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1011 - 1019
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1004 - 1012
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 830 - 838
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1119 - 1128
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 09/2014, Volume 120, Issue 17, pp. 2694 - 2703
Journal Article
Cancer Discovery, ISSN 2159-8274, 07/2018, Volume 8, Issue 7, pp. 822 - 835
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct... 
CTLA-4 BLOCKADE | CANCER-PATIENTS | MELANOMA | ONCOLOGY | COOCCURRING GENOMIC ALTERATIONS | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | NIVOLUMAB | LKB1 LOSS | DOCETAXEL | TUMOR MICROENVIRONMENT | non-small cell lung cancer | PD-1 blockade | STK11 | KRAS | LKB1 | lung adenocarcinoma
Journal Article
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2011, Volume 6, Issue 5, pp. 942 - 946
Journal Article
Journal Article